Abstract: In general, the invention features a method of marking a product for identification in which a marker, composed of an electroactive compound, is added to the product and subsequently measured using an electrochemical detector.

Abstract: A method of determining the concentration of an analyte in a sample, said method comprising bringing said analyte in contact with an indicator zone comprising a concentration gradient of a mobile binding member; and bringing said mobile binding member gradient into operable contact with a test zone comprising a fixed binding member, wherein a detectable signal that indicates the concentration of said analyte is produced.

Abstract: A method of monitoring a therapeutic regimen in an animal, the method involving a) providing to the animal a therapeutic compound and a detectable compound that passes into the bloodstream, excretory system, or other tissue or body fluid in detectable form; b) after a period of time, following step (a), sufficient for passage of a detectable amount of the detectable compound into the body fluid or tissue, collecting a sample of the fluid or tissue from the animal; and c) measuring or detecting the detectable compound, or a detectable metabolite thereof, in the sample, wherein the detectable compound involves one member of a specific binding pair, and detection is carried out using the second member of the specific binding pair.

Abstract: In general, the invention features a method of marking a product for identification in which a marker, composed of a print molecule, print molecule analogue, or molecularly imprinted molecule, are added to the product and subsequently measured in a specific binding assay.

Abstract: Methods for determining the concentration of an analyte in a sample in which an analyte gradient is established and brought into contact with one or more zones that contain binding members that interact with the analyte and thereby produce a detectable signal. Devices that may be used to practice the disclosed methods are also provided.

Abstract: Novel derivatives of chlorothalanil.RTM. (tetrachloroisophthalonitrile, TCPN), permit conjugation of the TCPN derivative to a carrier useful as an immunogen to induce antibodies specific for TCPN or a TCPN metabolite, or a screening antigen to detect such antibodies. Polyclonal and monoclonal antibodies specific for TCPN or a TCPN metabolite, as well as hybridoma cells producing such antibodies are disclosed. Also provided are immunoassay methods for detection and quantitation of pesticide chemicals, in particular, the fungicide TCPN or a TCPN metabolite, and kits containing a TCPN derivative screening antigen, an anti-TCPN or anti-TCPN metabolite antibody useful for performing the immunoassays.

Abstract: The invention relates to monoclonal antibodies that react specifically with members of the genus Mycosphaerella and hybridomas that produce such antibodies. The invention is further directed to a method for making a hybridoma cell line that produces monoclonal antibodies that react specifically with at least one species of Mycosphaerella, and a method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing Mycosphaerella infections in plant material using such monoclonal antibodies are also within the scope of the invention.

Abstract: The invention relates to monoclonal antibodies that react specifically with members of the genus Leptosphaeria and hybridomas that produce such antibodies. The invention is further directed to a method for making a hybridoma cell line that produces monoclonal antibodies that react specifically with Leptosphaeria nodorum, and a method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing Leptosphaeria infections in plant material using such monoclonal antibodies are also within the scope of the invention.

Abstract: A method for preparing a vaccine suitable for use in protecting lobsters against gaffkemia, which comprises:(a) culturing a logarithmic growth phase of the bacteria Aerococcus viridans (Var. Homari) in a suitable growth medium containing sources of assimilable complete nutrients for said bacteria;(b) adding a sublethal, replication-inhibiting amount of an antibiotic effective against said bacteria to said culture and incubating the resultant admixture for a period for time sufficient to accumulate antigens therein protective against gaffkemia infections; and(c) recovering said protective antigens to form a vaccine containing an immunologically effective amount of said antigens free of said living bacteria and substantially free of in vivo effective amounts of said antibiotic.